Humacyte, Inc. HUMA

0.56 (0.01) (1.75%) as of 25 Sep
Market cap
$166.7M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '17
P/E ratio
0.00 — — 0.00 0.00 0.00 — —
P/S ratio
74.50 — — 138.94 229.44 0.00 — —
P/FCF ratio
0.00 — — 0.00 0.00 0.00 — —
P/Operating CF
(5.81) — — (11.47) (13.51) (462.70) — —
P/B ratio
48.84 — — 1.86 2.37 1.13 — —
Price to Tangible BV
48.84 — — 1.86 2.37 1.13 — —
EV/Sales
81.59 — — 73.88 90.88 0.00 — —
EV/EBITDA
0.00 — — 0.00 0.00 0.00 — —
EV/Operating CF
(1.58) — — (1.63) (1.41) 0.00 — —
EV/FCF
(1.57) — — (1.60) (1.41) 0.00 — —
Quick Ratio
2.77 2.25 4.36 7.76 20.42 3.56 — —
Current Ratio
3.69 2.40 4.52 7.88 20.75 3.69 — —
Net Debt/EBITDA
(0.12) 0.29 0.70 1.51 2.46 0.30 — —
Debt/Assets
53.64% 9.88% 12.71% 19.18% 16.92% 21.64% 0.00% 0.00%
Debt/Equity
20.08 (0.26) 1.20 0.34 0.40 (0.07) — —
Asset Turnover
0.02 0.00 0.00 0.01 0.01 0.03 0.00 —
Operating CF/Net income
2.57 0.66 0.66 5.94 3.07 0.84 — —
Capex/Depreciation
(0.12) (0.22) (0.28) (0.11) (0.02) (0.03) — —
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 — —
ROE
164.78% 760.17% (169.81%) (10.01%) 23.21% 58.32% — —
ROA
(32.12%) (111.77%) (66.63%) (4.88%) (13.47%) (124.71%) 0.00% —
ROIC
(449.67%) 0.00% 0.00% (1,247.32%) 0.00% 0.00% — —
Return on Tangible Assets
(60.08%) (291.75%) (120.90%) (7.27%) (10.45%) (93.44%) — —
Average Days of Receivables
78.98 — — 7.23 50.86 27.66 — —
Research and Development Expense of Revenue
3,400.49% 0.00% 0.00% 4,042.17% 4,856.77% 3,626.96% — —
Selling, General and Administrative Expense of Revenue
1,529.49% 0.00% 0.00% 1,462.17% 1,673.00% 805.70% — —
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
478.56% 0.00% 0.00% 395.14% 803.33% 314.82% — —
Graham Net Nets
(0.30) — — 0.31 0.22 (0.07) — —
Graham Number
0.00 — — 0.00 0.00 0.00 — —
Earnings Yield
(20.83%) — — (5.69%) (91.86%) (0.20%) — —
Free Cash Flow Yield
(69.76%) — — (33.19%) (28.09%) 0.00% — —
Revenue per Share
0.01 0.00 0.00 0.02 0.03 0.26 — —
Operating CF per Share
(0.66) (0.83) (0.71) (0.69) (2.03) (9.64) — —
Capex per Share
(0.01) (0.01) (0.02) (0.01) (0.01) (0.05) — —
Free Cash Flow per Share
(0.67) (0.84) (0.73) (0.70) (2.04) (9.68) — —
Cash per Share
0.32 0.38 0.78 1.47 5.64 6.93 — —
Shareholders Equity per Share
0.02 (0.44) 0.13 1.13 3.06 (60.76) — —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 — —
Book value per Share
0.02 (0.44) 0.13 1.13 3.06 (60.76) — —
Free Cash Flow
(105.93) (99.69) (75.58) (72.18) (81.41) (55.84) — —
Working Capital
49.42 27.91 64.84 134.63 218.29 30.22 — —
Capital Expenditures
(0.88) (1.57) (2.28) (1.05) (0.22) (0.27) — —
Net Current Asset Value
(45.46) (142.68) (31.40) 66.83 64.98 (415.56) — —
EV/EBIT
0.00 — — 0.00 0.00 0.00 — —
Capex to Sales
0.43 0.00 0.00 0.67 0.17 0.18 — —
Net Profit Margin
(2,003.58%) 0.00% 0.00% (764.54%) (2,096.36%) (4,461.70%) — —
Price to Operating Income
0.00 — — 0.00 0.00 0.00 — —
Other line items
Depreciation/Fixed assets
0.40 0.31 0.31 0.32 0.26 0.20 — —
Cash ROIC
(106.52%) (2,058.17%) (90.76%) (32.85%) (29.34%) 33.60% — —
Accounts Receivable Turnover
8.64 — — 15.12 8.74 10.32 — —
Accounts Payable Turnover
1.96 0.00 0.00 4.48 3.79 3.86 — —
Inventory Turnover
0.00 — — 0.00 0.00 0.00 — —
Average Days of Payables
203.30 0.00 0.00 70.52 92.27 98.44 — —
Days of Inventory on Hand
511.23 — — 0.00 0.00 0.00 — —
Average Receivables
0.24 — — 0.10 0.14 0.14 — —
Average Payables
4.95 5.49 4.04 1.84 2.18 2.18 — —
Average Assets
127.12 133.05 166.26 245.42 196.61 53.34 0.00 —
Average Common Equity
(24.78) (19.56) 65.24 119.55 (114.07) (114.07) — —

Fold the line items

Columns are period end dates